Cancer Research Cancer Genome no Abstract  AM No Date
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vosseler, S.
Right arrow Articles by Fusenig, N. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vosseler, S.
Right arrow Articles by Fusenig, N. E.
[Cancer Research 65, 1294-1305, February 15, 2005]
© 2005 American Association for Cancer Research


Cell and Tumor Biology

Angiogenesis Inhibition by Vascular Endothelial Growth Factor Receptor-2 Blockade Reduces Stromal Matrix Metalloproteinase Expression, Normalizes Stromal Tissue, and Reverts Epithelial Tumor Phenotype in Surface Heterotransplants

Silvia Vosseler1, Nicolae Mirancea2, Peter Bohlen3, Margareta M. Mueller1 and Norbert E. Fusenig1

1 Division of Differentiation and Carcinogenesis (A080), German Cancer Research Center, Heidelberg, Germany; 2 Institute of Biology, Romanian Academy of Science, Bucharest, Romania; and 3 ImClone Systems, Inc., New York, New York

Requests for reprints: Norbert E. Fusenig, Division of Differentiation and Carcinogenesis (A080), German Cancer Research Center, INF 280, 69120 Heidelberg, Germany. Phone: 49-6221-42-4507/4519; Fax: 49-6221-42-4551; E-mail: n.fusenig{at}dkfz.de.

Inhibition of vascular endothelial growth factor (VEGF) signaling, a key regulator of tumor angiogenesis, through blockade of VEGF receptor (VEGFR)-2 by the monoclonal antibody DC101 inhibits angiogenesis, tumor growth, and invasion. In a surface xenotransplant assay on nude mice using a high-grade malignant squamous cell carcinoma cell line (A-5RT3), we show that DC101 causes vessel regression and normalization as well as stromal maturation resulting in a reversion to a noninvasive tumor phenotype. Vessel regression is followed by down-regulation of expression of both VEGFR-2 and VEGFR-1 on endothelial cells and increased association of {alpha}-smooth muscle actin–positive cells with small vessels indicating their normalization, which was further supported by a regular ultrastructure. The phenotypic regression of an invasive carcinoma to a well-demarcated dysplastic squamous epithelium is accentuated by the establishment of a clearly structured epithelial basement membrane and the accumulation of collagen bundles in the stabilized connective tissue. This normalization of the tumor-stroma border coincided with down-regulated expression of the stromal matrix metalloproteinases 9 and 13, which supposedly resulted in attenuated turnover of extracellular matrix components permitting their structural organization. Thus, in this mouse model of a human squamous cell carcinoma cell line, blockade of VEGF signaling resulted in the reversion of the epithelial tumor phenotype through stromal normalization, further substantiating the crucial role of stromal microenvironment in regulating the tumor phenotype.




This article has been cited by other articles:


Home page
Mol Cancer ResHome page
D. Belotti, C. Calcagno, A. Garofalo, D. Caronia, E. Riccardi, R. Giavazzi, and G. Taraboletti
Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer Invasion
Mol. Cancer Res., April 1, 2008; 6(4): 525 - 534.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
M. Mimeault and S. K. Batra
Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies
Ann. Onc., October 1, 2007; 18(10): 1605 - 1619.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Cheng, D.-H. Huo, D.-M. Kuang, J. Yang, L. Zheng, and S.-M. Zhuang
Human Macrophages Promote the Motility and Invasiveness of Osteopontin-Knockdown Tumor Cells
Cancer Res., June 1, 2007; 67(11): 5141 - 5147.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. J. Willhauck, N. Mirancea, S. Vosseler, A. Pavesio, P. Boukamp, M. M. Mueller, N. E. Fusenig, and H.-J. Stark
Reversion of tumor phenotype in surface transplants of skin SCC cells by scaffold-induced stroma modulation
Carcinogenesis, March 1, 2007; 28(3): 595 - 610.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Zhang, M. Jugold, E. C. Woenne, T. Lammers, B. Morgenstern, M. M. Mueller, H. Zentgraf, M. Bock, M. Eisenhut, W. Semmler, et al.
Specific Targeting of Tumor Angiogenesis by RGD-Conjugated Ultrasmall Superparamagnetic Iron Oxide Particles Using a Clinical 1.5-T Magnetic Resonance Scanner
Cancer Res., February 15, 2007; 67(4): 1555 - 1562.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
W. Lederle, H.-J. Stark, M. Skobe, N. E. Fusenig, and M. M. Mueller
Platelet-Derived Growth Factor-BB Controls Epithelial Tumor Phenotype by Differential Growth Factor Regulation in Stromal Cells
Am. J. Pathol., November 1, 2006; 169(5): 1767 - 1783.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Ansiaux, C. Baudelet, B. F. Jordan, N. Crokart, P. Martinive, J. DeWever, V. Gregoire, O. Feron, and B. Gallez
Mechanism of Reoxygenation after Antiangiogenic Therapy Using SU5416 and Its Importance for Guiding Combined Antitumor Therapy
Cancer Res., October 1, 2006; 66(19): 9698 - 9704.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. M. Gutschalk, C. C. Herold-Mende, N. E. Fusenig, and M. M. Mueller
Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Promote Malignant Growth of Cells from Head and Neck Squamous Cell Carcinomas In vivo
Cancer Res., August 15, 2006; 66(16): 8026 - 8036.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
D. W. Miller, S. Vosseler, N. Mirancea, D. J. Hicklin, P. Bohlen, H. E. Volcker, F. G. Holz, and N. E. Fusenig
Rapid Vessel Regression, Protease Inhibition, and Stromal Normalization upon Short-Term Vascular Endothelial Growth Factor Receptor 2 Inhibition in Skin Carcinoma Heterotransplants
Am. J. Pathol., November 1, 2005; 167(5): 1389 - 1403.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
F. Naef and J. Huelsken
Cell-type-specific transcriptomics in chimeric models using transcriptome-based masks
Nucleic Acids Res., July 19, 2005; 33(13): e111 - e111.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.